HOME >> BIOLOGY >> NEWS
Search for cholesterol absorption genes narrows to two chromosome regions

Two people eat the same egg, cheese and ham muffin for breakfast, yet one absorbs significantly more cholesterol into his or her blood than the other. Why?

The answer, and all of its implications for combating heart disease, remains stubbornly hidden within our DNA. In recent genetic studies with lab mice, however, researchers at The Rockefeller University have begun to close in on the culprit genes.

"By determining the genetic basis behind the observation that some people absorb 25 percent of cholesterol from their diet, while others absorb up to 75 percent, we hope to develop new treatments to protect this latter group," says senior co-author Jan. L. Breslow, M.D., head of The Rockefeller University's Laboratory of Biochemical Genetics and Metabolism and former national president of the American Heart Association.

The researchers hope that the identification of genes that regulate cholesterol absorption in mice will lead them to the location of similar genes in humans - and ultimately to the development of drugs that specifically reduce cholesterol absorption and protect against coronary heart disease, the number one cause of death in the United States.

In the Dec. 10 issue of the Proceedings of the National Academy of Sciences (published online Nov. 22), the Rockefeller scientists report the use of mouse "genetic linkage mapping" technology to narrow the location of genes responsible for regulating the absorption of plant fatty molecules called "plant sterols" - markers of cholesterol absorption - to two distinct regions on chromosome 2 and 14.

While the exact location of the genes has not been deduced, the results indicate that the researchers have indeed uncovered their general vicinity: one of the putative sites has an incredibly high probability - a billion to one - of carrying the suspected genes.

"We are excited because our data analysis shows that cholesterol absorption genes are very likely hiding in chr
'"/>

Contact: Whitney Clavin
clavinw@rockefeller.edu
212-327-7900
Rockefeller University
5-Dec-2002


Page: 1 2 3 4

Related biology news :

1. Search and destroy protein turns tables on HIV
2. Search for macular degeneration genes narrows
3. Search beneath lawns provides insight into backyard biodiversity
4. Searching for the real waterworld
5. Search for schizophrenia genes takes an unplanned turn
6. Searching for a genetic needle in a genome haystack
7. Searching for the secrets of drug-free transplants
8. Searching for new medications to treat alcoholism
9. Searching for biochemical markers in children of alcoholics
10. Search and support for the rare white abalone is on; sex must occur with close neighbors
11. Investigators Identify Suspect In Search For Stress-Sniffles Link

Post Your Comments:
(Date:4/27/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... first week of May, 2015 and will be fulfilling ... Gino Pereira , Chief Executive Officer ... as Wocket® enters the consumer market. We would like ...
(Date:4/20/2015)... PASADENA, Calif. , April 20, 2015 ... San Gabriel Valley to implant a new miniaturized, wireless ... HF System is the first and only FDA-approved heart ... reduce hospital admissions when used by physicians to manage ... a sensor that is implanted in the pulmonary artery ...
(Date:4/14/2015)... 2015  HYPR Corp. today announced it has ... Alliance tm , an industry consortium transforming online ... share technology and collaborate to deliver open specifications ... secure and private, and easier to use. ... protects sensitive user information and eliminates the dependency ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
(Date:5/21/2015)... , May 21, 2015  The EveryLife Foundation ... (R-UT) and Amy Klobuchar (D-MN) ... Accelerating Cures & Treatments, or OPEN ACT. ... patient advocacy organizations, this bipartisan legislation promises to ... medicines to rare disease patients by incentivizing drug ...
(Date:5/21/2015)... W. R. Grace & Co. (NYSE: ... Germany has received good manufacturing practice (GMP) certification ... Pharmaceutical Excipient Council (IPEC) Foundation. , ... FP brand of pharmaceutical grade excipient silica gels ... Bay, Maryland (USA) and Sorocaba, Brazil locations. The ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... May 20, 2015 Research and Markets ... of the "2015 Global Survey on Flow ... The primary goal of this research ... instruments and reagents. Key information the survey seeks ... of flow cytometers, predominantly used applications for flow ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2
Cached News: